RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

Leveraged Buyouts

A collection of news and information related to Leveraged Buyouts published by this site and its partners.

Top Leveraged Buyouts Articles

Displaying items 12-22
  • Botox-maker Allergan rejects takeover bid from Valeant

    Botox-maker Allergan Inc. said it rejected a takeover bid from Valeant Pharmaceuticals International Inc., a deal the company said undervalued its worth and posed significant risks to shareholders. Last month, the Irvine drugmaker received an...
  • Star India Reveals $3.2 Billion Sports Investment

    LONDON -- Star India, 21st Century Fox's pay TV subsid, has announced a 200 billion rupee ($3.2 billion) investment in the Indian sports business. Following News Corp's 2012 buyout of ESPN's 50 per cent share in the ESPN Star Sports joint venture...
  • The week ahead for December 9-15: Hilton IPO; quarterly industrial data; IP changes [Pictures]

    The week ahead for December 9-15: Hilton IPO; quarterly industrial data; IP changes [Pictures]
    (Reuters) - Hilton Worldwide Inc said its initial public offering would raise up to $2.37 billion in the biggest-ever hotel IPO, more than doubling Blackstone Group LP's investment. According to reports last week, Hilton is expected to launch its...
  • Ackman, Valeant partner in bid to buy Botox maker Allergan

    Activist investor Bill Ackman is partnering with a Canadian pharmaceutical company in an effort to buy Allergan Inc., the Irvine company that makes the popular wrinkle treatment Botox. Ackman and Valeant Pharmaceuticals International Inc. have already...
  • Ackman and Valeant make bid for Allergan

    Ackman and Valeant make bid for Allergan
    Activist investor Bill Ackman and his unlikely Canadian partner, Valeant Pharmaceuticals International Inc., unveiled details of their bid for Irvine pharmaceutical company Allergan Inc., which makes the popular Botox wrinkle treatment. Valeant will...
  • Allergan adopts 'poison pill' defense in Valeant takeover bid

    Takeover target Allergan Inc., the company that makes Botox, has adopted a "poison pill" defense intended to delay a buyout by Canadian company Valeant Pharmaceuticals International Inc. and activist investor Bill Ackman. The Irvine company's...
  • Transfer property into trust to avoid probate

    Q: Eleven years ago, my wife and I set up a trust and know we must restructure it now. We did not place our home in the trust, as I felt we would sell it and move to a smaller home. Why do we need a trust if our estate is way less than the $3 million...
  • Jos. Bank to be acquired by Men's Wearhouse for $1.8 billion

    Jos. Bank to be acquired by Men's Wearhouse for $1.8 billion
    Jos. A. Bank Clothiers finally liked the look of Men's Wearhouse's takeover offer as the Hampstead-based retailer accepted a $1.8 billion buyout Tuesday. The deal would pay Bank's stockholders $65 a share cash, $10 more than Men's Wearhouse initially...
  • Wall Street Sees More Shakeups Ahead After Comcast-TW Cable Deal

    Wall Street has been generally high on Comcast Corp. in recent months, but the immediate reaction to its mega-merger with Time Warner Cable was more focused on questions than applause. Comcast shares were down $2.28 at the close of trading Thursday to...
  • Investing: The Kiplinger 25: Merger Fund

    Does a stock fund that consistently generates low-single-digit returns deserve a place in the Kiplinger 25? The answer, we think, is yes -- if the fund in question practices a strategy that's so tame that its risk profile is closer to a medium-maturity...
  • Teel Time: Tom O'Brien rejoining Virginia football coaching staff; promotion for Hagans

    Teel Time: Tom O'Brien rejoining Virginia football coaching staff; promotion for Hagans
    Percolating for weeks, Tom O’Brien’s return to Virginia’s football coaching staff as associate head coach became reality Thursday. The final hurdle was O’Brien’s contract at North Carolina State, which fired him as head...